Jeffrey Hatfield

Hatfield currently serves as chief executive officer of Vividion Therapeutics, Inc. Previously, he was chief executive officer of Vitae Pharmaceuticals, Inc., where he led the company from start-up to clinical-stage advancement of multiple first-in-class programs, and ultimately to its $640 million acquisition by Allergan Plc. Prior to that, Hatfield worked at Bristol Myers Squibb in a variety of executive positions, including: Senior Vice President, Immunology and Virology Divisions; President and General Manager, BMS-Canada; and Vice President, U.S. Managed Health Care.